首页> 外国专利> Substituted pyrrolo2,1-aphthalazines and benzogpyrrolo2,1-aphthalazines for the treatment of cancer

Substituted pyrrolo2,1-aphthalazines and benzogpyrrolo2,1-aphthalazines for the treatment of cancer

机译:取代的Pyrrolo [2,1-a]酞嗪和苯并[g] pyrrolo [2,1-a]酞菁治疗癌症

摘要

Disclosed herein are novel bifunctional compounds and their uses for the treatment and/or prophylaxis of cancers. The bifunctional compound disclosed herein has the structure of formula (I),; embedded image wherein,; embedded image optionally substituted with one or more substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, C(O)H, OH, O(alkyl), O(CO)alkyl, O(aryl), aryl, and —O(CH2)xN(Rb)2;R1 is an alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo, —OR, —O(CO)CH3, —OSO2R, and —OCONHR;R is hydrogen, alkyl, cycloalkyl, or aryl;R2 is hydrogen, alkyl, cycloalkyl, aryl or heteroaryl, in which the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of C1-6 alkyl, O(alkyl), halo, cyano, nitro, —N(Rc)2, OCH2O—, O(CH2)2O—, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, and 4—(piperido)piperidinyl;R3 is -NRARB, or -NHPhRC, or -NRARB are taken together to form pyrrolidin-l-yl, piperidin-l-yl, piperazin-l-yl, morpholin-4-yl, 4-(piperidin-l-y)piperidin-l-yl, or 4-(piperidin-4-yl)piperidin-l-yl, wherein the piperazin-l-yl or 4-(piperidin-4-yl) piperidin-l-yl is optionally substituted with one or more substituents independently selected from the group consisting of alky, and —(CH2)nCONH(CH2)mNRARB;RA and RB are independently H or C1-C6 alkyl;RC is hydrogen, halo, alkyl, alkenyl, alknyl, O(alkyl), —NHCORa, —NHC(O)ORa, heterocyclyl or aryl, in which the alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl C(O)H, OC(O)alkyl, O(aryl), and aryl, in which the aryl is optionally substituted with one or more substituents independently selected from the group consisting of halo, CN, C1-6 alkyl, N(Rc)2, NO2, O(alkyl), —OCH2O—, —O(CH2)2O—,pyrrolidinyl, pepiridinyl, piperazinyl, morpholino, and 4-(piperido)piperidinyl;Ra is C1-6 alkyl or aryl;Rb is C1-10 alkyl, pyrrolidin-l-yl, piperidin-l-yl, piperazin-l-yl, morpholin-4-yl, 4-(piperidin-l-yl)piperidin-l-yl, or 4-(piperidin-4-yl)piperidin-l-yl;Rc, is hydrogen or C1-10 alkyl; and.x, n and m are independently an integral between 1 to 5.
机译:本文公开了新型双官能化合物及其用于治疗和/或预防癌症的用途。本文所公开的双官能化合物具有式的结构(I),; <化学ID =“Chem-US-00001”> <图像ALT = “嵌入图象” 文件= “US11066412-20210720-C00001.GIF” 他= “33.10毫米” imgContent = “CHEM” imgFormat = “GIF” 无线= “54.10毫米”/> 其中,; <化学ID =“Chem-US-00002”> <图像ALT = “嵌入图象” 文件= “US11066412-20210720-C00002.GIF” 他= “52.66毫米” imgContent = “CHEM” imgFormat = “GIF” 无线= “45.97毫米”/> 任选地被一个或多个取代基独立地选自卤素,烷基,卤代烷基,链烯基,C(O)H,OH,O(烷基),O(CO)烷基,O(芳基),芳基组成的组中取代,以及 - O(CH <子> 2 )<子> X N(R <子> b'/子>)<子> 2 ; <列表项ID = “ul0001-0001” 号= “0000”> - [R 1 任选地被一个或多个取代基取代的烷基独立地选自自由卤基,-OR,-O(CO)CH <子> 3 ,-OSO <子> 2 R,-OCONHR和 <列表项ID =“ul0001 -0002" 号= “0000”> R是氢,烷基,环烷基,或芳基; <列表项ID = “ul0001-0003” 号= “0000”> - [R 2 是氢烷基,环烷基,芳基或杂芳基,其中所述芳基或杂芳基任选地被从由C <子> 1-6 烷基,O(烷基),卤代的基团独立地选择的一个或多个取代基取代,氰基,硝基,-N(R <子> C )<子> 2 ,OCH <子> 2 O-,O(CH <子> 2 ) <子> 2 O-,吡咯烷基,哌啶基,哌嗪基,吗啉代,和4-(piperido)哌啶基; <列表项ID = “ul0001-0004” 号= “0000”> - [R 3 是-NR A - [R ,或-NHPhR <燮> C ,或-NR A ř 结合在一起形成吡咯烷-1-基,哌啶-1-基,哌嗪-1-基,吗啉-4-基,4-(哌啶LY)哌啶-1-基,或4-(哌啶吡啶-4-基)哌啶-1-基,其中所述哌嗪-1-基或4-(哌啶-4-基)哌啶-1-基任选被选自烷基的组中独立选择的一个或多个取代基取代,和 - (CH <子> 2 )<子>名词 CONH(CH <子> 2 )<子>米 NR A ř ; <列表项ID = “ul0001-0005” 号= “0000”> - [R A 和R 独立地是H或C <子> 1 -C <子> 6 烷基; <列表项ID = “ul0001-0006” 号= “0000”> - [R <燮> C 是氢,卤素,烷基,烯基,alknyl,O(烷基), - NHCOR <子>一,-NHC(O)OR <子>一,杂环基或芳基,其中所述烷基任选地被选自卤素,烷基,卤代烷基,链烯基C(O)H,OC(O)烷基,O(芳基),和芳基的基团,其中所述芳基是任选取代的独立选择的一个或多个取代基取代用一个或多个取代基独立地选自卤素基,CN,C <子> 1-6 烷基,N(R <子> C )<子> 2 , NO <子> 2 ,O(烷基), - OCH <子> 2 O-,-O(CH <子> 2 )<子> 2 0 - ,吡咯烷基,pepiridinyl,哌嗪基,吗啉代,和4-(piperido)哌啶基; <列表项ID = “ul0001-0007” 号= “0000”> - [R <子>一是C <子> 1-6 烷基或芳基; <列表项ID = “ul0001-0008” 号= “0000”> - [R <子> b'/子>是C <子> 1-10 烷基,吡咯烷-1-基,哌啶-1-基,哌嗪-1-基,吗啉-4-基,4-(哌啶-1-基)哌啶-1-基,或4-(哌啶-4-基)哌啶-1-基 <列表项ID = “ul0001-0009” 号= “0000”> - [R <子> C ,为氢或C <子> 1-10 烷基;和 <列表项ID = “ul0001-0010” 号= “0000”> X,n和m独立地为5至1之间的积分。

著录项

  • 公开/公告号US11066412B2

    专利类型

  • 公开/公告日2021-07-20

    原文格式PDF

  • 申请/专利权人 ACADEMIA SINICA;

    申请/专利号US201816764873

  • 发明设计人 TE-CHANG LEE;TSANN-LONG SU;TAI-LIN CHEN;

    申请日2018-11-16

  • 分类号C07D487/14;C07D487/22;C07D487/04;A61P35/02;A61K45/06;

  • 国家 US

  • 入库时间 2022-08-24 20:01:34

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号